Members' News Members were informed that membership letters were due to be sent out before the end of the month.
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Letrozole Tablets (Minute 161) A laboratory report was pending for the development of an IR identification test and for the assessment of the LC Related substances and Assay procedure.
Prolonged-release Galantamine Capsules, Galantamine Oral Solution and Galantamine Tablets (Minute 161)
A laboratory report was pending for the development of Related substances and Assay procedures.
Neomycin and Chlorhexidine Nasal Cream (Minute 161)
Further work on this monograph had been deferred pending further consultation with the sole UK MAH.
Quinapril Tablets (Minute 161) A laboratory report was pending for the assessment of the LC Related substances procedure.
Carprofen Injection and Tablets (Minute 161)
A laboratory report was pending for the assessment of the infrared identification, LC Related substances and Assay procedures. The monographs had been circulated to the VMD and stakeholders for comments; no comments had been received at the time of the meeting.
Propranolol Oral Solution (Minute 161)
The Secretariat was awaiting the response of the sole UK MAH for this product.
Sulfasalazine Oral Suspension (Minute 161)
The Secretariat had requested the cooperation of the UK MAH for this product.
Verapamil Oral Solution (Minute 161)
Prolonged-release Tamsulosin Tablets (Minute 161)
A laboratory report was pending for the assessment of the LC Related substances procedure.
Benazepril Tablets (Minute 161) A laboratory report was pending for the assessment of the drafted identification, Related substances and Assay procedures.
Fluvastatin Sodium Capsules and Prolonged-release Tablets (Minute 161) A laboratory report was pending for the identification, Related substances and Assay procedures.
Ibuprofen and Codeine Tablets (Minute 161)
A laboratory report was pending for the identification, Related substances and Assay procedures.
Ketoprofen Injection and Tablets (Minute 161)
The monograph had been amended and circulated to MAHs, no comments had been received at the time of the meeting. A laboratory report was pending for the identification, Related substances and Assay procedures. Members were presented with a paper on the emergency evacuation procedure.
187

BP 2015 MC2(14)23
Members were informed that the BP 2015 had been published in August 2014 and would come into effect on 1 st January 2015.
188
Membership MC2(14)24
Members were asked to confirm their contact details were correct and inform the Secretariat of any amendments required.
189
BP Laboratory MC2(14)25
A list of several reference materials relating to monographs within the remit of EAG MC2, which had been adopted since the meeting of 22 nd May 2014, was provided for information.
190
Current Work Programme MC2(14)26
A list of initiated monographs for EAG MC2 was provided for information.
191
Gliclazide Tablets MC2(14)27
The monograph for Gliclazide Tablets had been amended to cross refer the name of the specified impurity in the Related substances to the relevant EP impurity code (EP impurity F), the BPCRS and relevant information leaflet had also been updated accordingly. The revised monograph would be published in the BP 2016.
192
Ramipril Impurity K MC2(14)28
The Secretariat reported that the BP Laboratory had encountered difficulties in establishing a replacement Ramipril Impurity K BPCRS. This BPCRS was required by the Related substances procedure in the Capsules and Tablets product monographs.
IV NEW MONOGRAPHS
193
Rivastigmine Preparations MC2(14)29
The draft monographs would be included in a future BP publication, subject to comments.
V MONOGRAPHS IN PROGRESS
194
Anastrozole Tablets MC2(14)30
The draft monograph would be included in a future BP publication, subject to comments.
195
Aprepitant Capsules MC2(14)31
196
Carvedilol Tablets MC2(14)32
The draft monograph would be included in a future BP publication, subject to comments. The draft monograph would be included in a future BP publication, subject to comments.
198
Olmesartan Tablets MC2(14)34
199
Risedronate Tablets MC2(14)35
200
Temozolomide Capsules Temozolomide Injection
MC2(14)36
VI REVISION OF MONOGRAPHS
201
Adrenaline/Noradrenaline Preparations MC2(14)37
Mr Sean Jones from the Licensing Division attended the meeting for this paper.
It had been previously reported at the May 2014 meeting of EAG: MC2 that the Adrenaline and Noradrenaline family of drug product monographs had been under review by this EAG for several years and that the Licensing Division had since requested that the determination of content for adrenaline products was also reviewed.
The MHRA Laboratory had developed a protocol to investigate ratios of the inactive D-adrenaline and active L-adrenaline isomers. Several pharmaceutical forms would be assessed using a chiral HPLC method drafted by the Secretariat, published Assay methods and methods proposed by manufacturers.
The outcomes of this protocol should lead to a better understanding of the content and impurity profiles. The intention would be to share the conclusions of this work with other pharmacopoeias and regulators, if appropriate.
202
Aminophylline MC2(14)38
The Secretariat had received a query from a manufacturer regarding the content limits for theophylline in the Aminophylline Injection monograph. A similar query regarding the content limits for ethylenediamine in the Aminophylline Tablets monograph had been raised and it was proposed that both content statements for the Aminophylline family of monographs were reviewed at the same time.
Aminophylline is a complex of 2 molecules of theophylline and 1 molecule of ethylenediamine with a variable proportion of water. The Ph. Eur. parent monographs (Aminophylline and Aminophylline Hydrate) as well as the Aminophylline Tablet and Prolonged-release Aminophylline Tablet monographs are written in terms of Anhydrous Aminophylline, "Aminophylline".
Theophylline content
The theophylline content limits of 73.25 to 88.25% of the stated amount of Aminophylline in the Aminophylline Injection monograph had remained unchanged since at least the BP 1963. At that time, "Aminophylline" referred to the hydrated form (mono or di) and would have been equivalent to a limit of 80.75 +/-10% which was assumed to have allowed for use of both the monohydrate (82.18) and dihydrate (78.94).
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Ethylenediamine content Members agreed with the Secretariat proposal to revise the content limits in line with the parent monographs, with the exception of the Injection monograph for which an excess of ethylenediamine is present in the Injection formula for solubility purposes.
203
Alendronic Acid Tablets MC2(14)39
The Secretariat had previously reported at the November 2012 meeting of EAG: MC2 that a number of laboratories and manufacturers had reported difficulties with the current Related substances and Assay procedures. The BP Laboratory was asked to perform an investigation of the Phosphate/Phosphite and Assay method specified in the Ph Eur parent monograph and that work had now been successfully completed and the monograph amended accordingly.
204
Levothyroxine MC2(14)40
Dr Ruggerio provided a brief oral update on current discussions in the Licensing Division on Levothyroxine products.
205
Perindopril Erbumine Tablets MC2(14)41
The Secretariat had previously received a request for revision of the limits for impurity B and F from a manufacturer. The revised monograph had been circulated to manufacturers and responses had been received from two additional MAHs. Members agreed that the revision should not proceed until a response was received from the manufacturer who raised the request for revision.
206
Simvastatin Oral Suspension MC2(14)42
The monograph for Simvastatin Oral Suspension had been published in the BP 2015. Members had agreed at the November 2013 meeting that manufacturer should be asked to submit long-term stability data to support their request for amended pH limits; this data had now been supplied.
Members agreed that the pH specification was not required and should be deleted from the draft monograph. This was based on data which demonstrated that pH did not have a significant effect on the product stability.
VII EUROPEAN PHARMACOPOEIA
207
Comments on draft monographs of the Ph Eur.
MC2(14)43
It was noted that the following European Pharmacopoeia monographs for which Expert Advisory Group MC2 has responsibility had been published in Pharmeuropa for comments: 
